There is an urgent need to develop sensitive and specific biomarkers of response to treatment in oncology. This thesis explores the utility of three novel positron emission tomography (PET) radiotracers: [18F]-3'deoxy-3'fluorothymidine (FLT), [11C]choline and [18F]-AH111585. All patients in the PET studies had breast cancer. Aims: 1) To quantify the uptake and retention of [18F]FLT, [11C]choiine and [18F]-AH111585 in breast cancer, and evaluate the role of mathematical modelling compared to standard techniques for quantifying tracer uptake. 2) To correlate [18F]FLT and [11C]choiine PET data with immunohistochemical markers of proliferation. 3) To establish if [18F]FLT and [11C]choline PET are reproducible in breast cancer. 4) To determine...
Many new breast-cancer treatment strategies are not based on traditional anti-proliferative effects ...
The paradigm of drug development is shifting towards early use of imaging biomarkers as surrogate en...
Purpose: The suitability of [18F]FDG, [18F]FLT, [18F]FET, and [18F]FCH as non-invasive positron emis...
Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cell...
AbstractImaging biomarkers have a potential to depict the hallmarks of cancers that characterise can...
BACKGROUND:In breast cancer endocrine therapy, post-therapy Ki-67 assay of biopsy material predicts ...
Positron emission tomography (PET) imaging has emerged as an important decision-making tool in onco...
Positron emission tomography (PET) enables noninvasive tumour imaging, as changes in metabolic activ...
INTRODUCTION: The aims of this study were to investigate whether drug sequence (docetaxel followed b...
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of breast cancers (BC...
Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 ...
Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 ...
In clinical breast cancer, endocrine therapy and cytotoxic chemotherapy are the mainstay of treatmen...
Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 ...
Background: This pilot study investigated the feasibility of F-18-3'-deoxy-3'-fluoro-L-thymidine (F-...
Many new breast-cancer treatment strategies are not based on traditional anti-proliferative effects ...
The paradigm of drug development is shifting towards early use of imaging biomarkers as surrogate en...
Purpose: The suitability of [18F]FDG, [18F]FLT, [18F]FET, and [18F]FCH as non-invasive positron emis...
Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cell...
AbstractImaging biomarkers have a potential to depict the hallmarks of cancers that characterise can...
BACKGROUND:In breast cancer endocrine therapy, post-therapy Ki-67 assay of biopsy material predicts ...
Positron emission tomography (PET) imaging has emerged as an important decision-making tool in onco...
Positron emission tomography (PET) enables noninvasive tumour imaging, as changes in metabolic activ...
INTRODUCTION: The aims of this study were to investigate whether drug sequence (docetaxel followed b...
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of breast cancers (BC...
Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 ...
Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 ...
In clinical breast cancer, endocrine therapy and cytotoxic chemotherapy are the mainstay of treatmen...
Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 ...
Background: This pilot study investigated the feasibility of F-18-3'-deoxy-3'-fluoro-L-thymidine (F-...
Many new breast-cancer treatment strategies are not based on traditional anti-proliferative effects ...
The paradigm of drug development is shifting towards early use of imaging biomarkers as surrogate en...
Purpose: The suitability of [18F]FDG, [18F]FLT, [18F]FET, and [18F]FCH as non-invasive positron emis...